AG
TEVA icon

AIA Group’s Teva Pharmaceuticals TEVA Stock Holding History

AIA Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,061
Closed -$80.2K – 479
2023
Q1 		$80.2K Hold
9,061
– – ﹤0.01% 376
2022
Q4 		$82.6K Sell
9,061
-4,485
-33% -$39.1K 0.01% 374
2022
Q3 		$109K Sell
13,546
-8,400
-38% -$74.3K 0.01% 362
2022
Q2 		$165K Buy
21,946
+4,725
+27% +$41.2K 0.01% 397
2022
Q1 		$162K Buy
17,221
+4,762
+38% +$39.7K 0.01% 410
2021
Q4 		$100K Hold
12,459
– – ﹤0.01% 417
2021
Q3 		$121K Buy
+12,459
New +$117K 0.01% 263

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AIA Group's TEVA Position: Q2 2023 in Review

AIA Group sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 9,061 shares — an estimated $80.2K sold.

AIA Group first reported a position in TEVA in Q3 2021 and held it in 7 quarters. The position peaked at $165K in Q2 2022. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • AIA Group reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • AIA Group sold 9,061 Teva Pharmaceuticals shares in Q2 2023, an estimated $80.2K.
  • AIA Group first reported a position in Teva Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • AIA Group's Teva Pharmaceuticals position peaked at $165K in Q2 2022.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on AIA Group's 13F filing for Q2 2023, filed 28 Jul 2023.